Targeting the Tumor Microenvironment With Src Kinase Inhibition

Targeting the tumor microenvironment with SRC kinase inhibition.

Although most cancer therapies are directed against tumor cells, an emerging area of cancer therapeutics focuses on targeting cells of the tumor microenvironment. Inhibiting the Src family kinase with dasatinib decreases tumor growth through inhibiting growth of tumor-associated endothelial and myeloid cells.

Targeting the tumor microenvironment.

Despite some notable successes cancer remains, for the most part, a seemingly intractable problem. There is, however, a growing appreciation that targeting the tumor epithelium in isolation is not sufficient as there is an intricate mutually sustaining synergy between the tumor epithelial cells and their surrounding stroma. As the details of this dialogue emerge, new therapeutic targets have be...

Targeting the tumor microenvironment

Persistent JAK-STAT3 signaling is implicated in many aspects of tumorigenesis. Apart from its tumor-intrinsic effects, STAT3 also exerts tumor-extrinsic effects, supporting tumor survival and metastasis. These involve the regulation of paracrine cytokine signaling, alterations in metastatic sites rendering these permissive for the growth of cancer cells and subversion of host immune responses t...

Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.

PURPOSE Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor microenvironment and how these effects influence tumor growth. EXPERIMENTAL DESIGN Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor o...

Effect of Host Src-kinase Inhibition on Replication of Coxsackievirus B3 in vitro